The efficacy of a tumor-specific immune response is influenced by the balance between tumor-infiltrating regulatory T cells (Treg) and tumor infiltrating CD4+ and CD8+ T cells (reviewed in Takeuchi and Nishikawa1). This evidence concerns the gene CD8A and neoplasm.